Bristol Myers Squibb Presents Positive Phase 3 Data for KarXT in Alzheimer's Psychosis
Rapid Read

Bristol Myers Squibb Presents Positive Phase 3 Data for KarXT in Alzheimer's Psychosis

What's Happening? Bristol Myers Squibb has announced preliminary Phase 3 findings from its ADEPT program, evaluating KarXT (xanomeline and trospium chloride) for the treatment of psychosis associated with Alzheimer’s disease. Data from the 12-week open-label period of the ADEPT-1 study and the 52-we
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.